Navigation Links
Anapol Schwartz Attorney Representing Trasylol(R) Victims Says Medical Study - Confirming Heart Bypass Drug Mortality Risk - to Open Floodgates for More Litigation
Date:2/20/2008

PHILADELPHIA, Feb. 20 /PRNewswire/ -- According to Anapol Schwartz (http://www.anapolschwartz.com/) attorney James Ronca (http://www.anapolschwartz.com/attorneys/jim_ronca.shtml), a New England Journal of Medicine study (http://content.nejm.org/cgi/content/short/358/8/771?query=TOC) (to be released in the February 21, 2008, print edition) confirms that Bayer AG's blood-clotting drug Trasylol(R), used in coronary artery bypass graft (CABG) procedures, causes kidney/renal failure and increases mortality risk. While initial findings of the study, commissioned by Bayer, were sent to the drug company and the FDA in 2006, this is the first time the final results have been published in full.

Ronca, who is one of the chairs of the national Trasylol(R) litigation, and represents a dozen families and victims (see Trasylol(R) lawsuit (http://www.anapolschwartz.com/practices/trasylol/) and a recent wrongful death complaint (http://www.anapolschwartz.com/practices/trasylol/thompson-complaint.pdf) filed in Philadelphia), argues this study reinforces inherent problems in the FDA's screening process and opens the floodgates for additional litigation.

"According to published sources, thousands may have died from Trasylol(R), when this could have been prevented. Again, we have another example of the FDA not protecting the public -- and the safety of individuals taking a back seat to company profits," says Ronca, who leads advocacy initiatives to raise awareness about Trasylol's(R) side effects.

Pulled by Bayer from the market in November 2007 in response to FDA concerns, Trasylol(R) is administered by an anesthesiologist during CABG surgery (http://www.anapolschwartz.com/practices/trasylol/thompson-complaint.pdf) to limit bleeding. Affected patients typically experience kidney/renal failure symptoms within 48 hours. Many, however, are unaware they have received the drug, complicating diagnosis.

"These findings should further educate the public about Trasylol's(R) dangers, and open the door for victims, and those who don't realize they are victims, to receive remuneration for their injuries," stresses Ronca, who has served as counsel to victims in product liability cases involving Baycol, LOTRONEX, hormone replacement therapy and breast implants.

Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley is a personal injury firm with law offices in Philadelphia, Reading, Media, and Harrisburg, Pa., as well as Cherry Hill, N.J. (http://www.anapolschwartz.com/contactus.shtml) The firm is a multi-faceted practice with a tradition of excellence in medical malpractice law, pharmaceutical mass tort, toxic tort, class actions, products liability, automobile, securities and wrongful termination litigation. Since its founding in 1977, the firm has grown to over 30 attorneys, and compiled a record of success exceptional among its peers.

Contact: Alexandra Kane-Weiss/Jennifer Wasilisin

215-793-4666

akaneweiss@startoplin.com

jwasilisin@startoplin.com


'/>"/>
SOURCE Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Consumer Driven Healthcare Continues To Make Its Mark on Indianapolis Market
2. St.Vincent and Publicis Indianapolis Receive National Service Industry Advertising Awards
3. Brown Mackie College - Indianapolis Announces New Degree Program in Occupational Therapy
4. Community Health Network of Indianapolis Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
5. Tobacco-Free Kids Indiana Action Fund Launches Campaign in Support of Angela Mansfield and Scott Keller for Indianapolis City-County Council
6. Pennsylvania Attorney General Corbett Announces Multi-State Settlement With Caremark
7. AHIP Statement on New York Attorney Generals Announcement
8. Pennsylvania Attorney General Approves Vincentian Collaborative System-Marian Manor Integration
9. Former FTC Attorney Christine White Joins Crowell & Morings Health Care and Antitrust Groups
10. Elder Care Operator and Plaintiff Attorney Announce Unprecedented Settlement Agreement in Class Action Lawsuit
11. Statement from AAJ President Kathleen Flynn Peterson on ATRAs Latest Attack on Civil Justice Attorneys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Qrono Inc. ... announced a development collaboration with the Australian critical medicine company, Phebra Pty ... schizophrenia. , LAI medicines can offer improved therapeutic benefits over oral formulations, including ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... Tampa to offer patients with non-valvular atrial fibrillation (A-Fib) an alternative to long-term ... Since first offering the procedure in April of 2015, Florida Hospital Pepin Heart ...
(Date:5/5/2016)... Kansas (PRWEB) , ... May 05, 2016 , ... ... that some macroalgae can use ultraviolet light A (UV-A) for photosynthesis, researchers Juntian ... of red, green, and brown seaweeds. The pair observed that when photosynthetically active ...
(Date:5/5/2016)... ... May 05, 2016 , ... Derrin Doty Group has ... of Bremerton, Port Orchard and communities west of Seattle. The insurance provider’s caring team ... local girl who died suddenly due to complications from the flu, that they have ...
(Date:5/5/2016)... ... May 05, 2016 , ... The University of Western ... host the 2016 National SACA Leadership Conference on the Portland campus September 23-25. ... officers to come together and develop skills to be future leaders in the ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)...  As a teenager, an active and athletic ... his heart. He continued enjoying sports and recreation throughout ... heart was giving out and he was a few ... the Mesa, Arizona resident received ... heart transplant, the SynCardia TAH-t is the only approved ...
(Date:5/3/2016)... 3, 2016   BIOTRONIK , a leader ... Food and Drug Administration (FDA) approval of Iperia ... heart failure patients with access to diagnostic magnetic ... remote monitoring with daily automatic transmission and closed ... in response to physiological demands. ...
(Date:5/3/2016)... 2016   BIOTRONIK will be exhibiting and ... the implant at the Heart Rhythm Society,s 37 th ... San Francisco . "Physicians and ... of patient care and satisfaction possible. Part of that ... every tomorrow," said Marlou Janssen , President, BIOTRONIK, ...
Breaking Medicine Technology: